REVIER Therapeutics
Revier Therapeutics (“Revier”, the “Company”, “we” or “us”) attributes great importance to the protection of your personal data. Therefore, we exclusively process personal data in compliance with the applicable laws, in particular with the EU- General Data Protection Regulation (“GDPR”). This Privacy Policy provides information about how we process personal data when visiting or using our website www.revier.bio (the “Website”).
Data Controller according to Art. 4 No. 7 GDPR is:
Revier Therapeutics GmbH
Nikola-Tesla-Str. 1
69124 Heidelberg, Germany
Telephone: +49 6221 3522991
E-mail: info@revier.bio
If you contact us by e-mail or via a contact form, the personal data provided by you (your e-mail address, and if necessary, your name and your phone number) will be stored by us on the basis of Art. 6 (1) (b) GDPR in order to answer your questions. These personal data will be deleted after storage is no longer required or processing will be restricted if there are statutory retention and documentation obligations.
If you only use the Website for informational purposes, i.e. if you do not register or otherwise provide us with information, we only process the personal data that your browser transmits to our server. If you wish to view our Website, we process the following data on the legal basis of Art. 6 (1) (f) GDPR which is technically necessary for us to display our Website to you and to guarantee stability and security: IP address, Date and time of the request, Content of the request (concrete page), Access status / http status code, the amount of data transferred in each case, the website from which the request comes, Browser type and browser version, operating system and its interface, Language and version of the browser software.
When you visit our Website, cookies may be stored on your device in order to provide us with personalised functions and to analyse your use of our Website. Cookies are used on the basis of Art. 6 (1) (f) GDPR. A cookie is a small text file that is stored on a user’s device (computer, tablet, smartphone etc.) in order to store certain information relating to the user’s device. If our Website is accessed by the corresponding device of the user, the server of our Website receives cookies back. The server can evaluate the information stored in cookies in various ways. Cookies can be used, for example, to collect statistical data on website usage. Cookies cannot execute programs or transmit viruses to your device. Cookies cannot access, read or modify any other data on your device.
Our Website uses technical and functional cookies to ensure that certain functionalities of the Website work properly. We also use Session ID cookies to distinguish you from other users of our Website. The use of cookies enables us to make our Website more user-friendly and also allows us to improve the Services.
You can allow, block or delete cookies installed on your device by setting the browser options installed on your device. Please read the help section of your browser carefully to learn more about how to activate the “Private mode” or unlock certain cookies. Here are some examples from well-known browsers to change your settings: a) Internet Explorer: Tools > Internet Options > Privacy > Configuration. For more information, please consult Microsoft support or browser help. b) Firefox: Tools > Options > Privacy > History > Custom Settings. For more information, please consult Mozilla support or browser help. c) Chrome: Settings > Show Advanced Options > Privacy > Content Settings. For more information, please consult Google support or browser help. d) Safari: Preferences > Privacy. For more information, please consult Apple support or browser help.
We use a number of external web services on our Website. For example, we may refer to external patient organizations. If you visit these other websites, their privacy and cookie policies apply to the processing of your personal data in this regard.
We maintain reasonable security procedures within the meaning of Art. 32 GDPR in order to protect the personal data you provide to us against loss, misuse, unauthorized access, disclosure, alteration or destruction.
We process your personal data no longer than it is necessary to achieve the purposes for which they were processed. However, your personal data can also be stored if this is provided for by the legal requirements to which we are subject, for example with regard to statutory retention and documentation obligations. In such a case, we will delete or block your personal data after the end of the respective requirements.
As a data subject You have the following rights: the right to access your personal data processed by us (Art. 15 GDPR); the right to request the rectification (Art. 16 GDPR) or erasure (Art. 17 GDPR) of your personal data; the right to request that we restrict the processing of your personal data (Art. 18 GDPR); the right to object to the further processing of your personal data (Art. 21 GDPR); the right to transmit your personal data to another controller (Art. 20 GDPR); the right to not to be subject to a decision based solely on automated processing, including profiling, which produces legal effects concerning you or similarly significantly affects you (Art. 22 GDPR). You have the right to lodge a complaint with a supervisory authority if you take the view that the processing of your personal data is unlawful (Art. 77 GDPR).
Your right to withdraw consent: Where the processing of your personal data by us is based on consent, you have the right according to Art. 7 GDPR to withdraw that consent without detriment at any time by contacting us at info@revier.bio. The withdrawal of consent does not affect the lawfulness of processing based on consent before its withdrawal.
Last update: August 2026
Scientific founder
Johannes is a cardiovascular scientist whose discoveries have advanced our understanding of cardiobiology and led to new therapeutic concepts for cardiogenetic and cardiometabolic disease. Over the past two decades, his research has uncovered fundamental mechanisms linking epigenetics, metabolic stress, inflammation to CaM Kinase II and HDAC signaling as causes for cardiac dysfunction. Johannes is the Director of the Institute of Experimental Cardiology at Heidelberg University, professor of the German Centre for Cardiovascular Research (DZHK), Director (interim) of the Helmholtz Institute for Translational AngioCardioScience (HI-TAC) and Spokesperson of the Collaborative Research Center „Molecular Circuits of Heart Disease“ (CRC1550).
He holds an MD in Medicine from Heidelberg University.
Norbert is a physician-scientist and clinical cardiologist with extensive experience in cardiovascular medicine and translational research. From 2008 to 2020, he served as Professor and Medical Director at the University Medical Center Schleswig-Holstein (Kiel). Since 2020, he has been Professor and Medical Director of the Department of Cardiology, Angiology and Pneumology at the Heidelberg University Hospital. He is also President-elect of the German Cardiac Society (DGK). His research focuses on the molecular basis of cardiomyopathies and heart failure and on translating these insights into improved therapies for cardiovascular disease. He has initiated and participated in numerous clinical trials.
He holds an MD in Medicine/Pharmacology from the University of Kiel.
Matthias is a physician-scientist with extensive experience in translational cardiovascular research. He serves as the Head of the Preclinical In Vivo Model Core at the Institute of Experimental Cardiology, Heidelberg University Hospital, where he has contributed to the discovery and preclinical development of novel experimental approaches for heart failure and cardiometabolic disease over the past decade. His research focuses on the molecular mechanisms underlying heart failure, cardiac metabolism, and cardiometabolic disease, with the goal of translating biological insights into new therapeutic strategies.
He holds an MD in Medicine/Pharmacology from the University of Goettingen.
Mike is an experienced biotechnology executive with more than 20 years of drug discovery and company-building experience. He served as the VP of Biology at Valence Discovery when it was acquired by Recursion. Between 2018 and 2023, he was Entrepreneur-in-Residence at Atlas Venture, where he co-founded Quench Bio and led its biology and early drug discovery efforts, then built industrialized proteomics as a founding-stage team member at Matchpoint. Earlier in his career, he held scientific leadership positions at GSK, Tempero Pharmaceuticals, Ascent Therapeutics and Wyeth, advancing therapeutics across inflammation, immunology, oncology and fertility indications.
He holds a Ph.D. in Pharmacology from the University of Washington.
CO-FOUNDER & CHIEF EXECUTIVE OFFICER
Eva is a serial entrepreneur bringing extensive experience at the intersection of biotechnology development, drug discovery, and cardiovascular translational research to Revier. Her pioneering work on cardiac microRNAs contributed to the scientific foundation of miRagen Therapeutics, one of the first companies developing microRNA-based medicines for cardiovascular disease, and subsequently to the founding of Phlox Therapeutics. Eva is Professor of Molecular Cardiology at University Medical Center Utrecht and a Group Leader at the Hubrecht Institute, where her research aims to identify signaling pathways that drive cardiac remodeling and repair and to translate these discoveries into new therapeutic strategies.
She holds a Ph.D. in Molecular Biology from Maastricht University.
Our earliest-stage drug discovery programs are focused on isoform selectivity within the class IIa HDACs, with the goal of advancing additional first-in-class assets for cardiometabolic diseases and beyond.
Our second asset is a class IIa HDAC inhibitor optimized to selectively target disease-driving mechanisms and maximize therapeutic benefit in atherosclerotic cardiovascular disease (ASCVD).
Our lead class IIa HDAC inhibitor selectively targets enzymatic activity to address the underlying drivers of heart failure with preserved ejection fraction (HFpEF). Preclinical studies show our lead inhibitor reverses diastolic dysfunction and restores exercise capacity to healthy levels in vivo.
